Insider · CIK 0001383731

MacLean Michael F

Reports to the SEC for 6 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001383731

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-01	CAMPCamp4 Therapeutics Corp · Stock Option (Right to Buy)A Award	Director	AAward	+56K sh	—	—	56,000
2026-02-27	RNAMAvidity Biosciences, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−134K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−50K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−106K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−60.1K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−148K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−131K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−92K sh	—	—	0
2026-01-21	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−1,807 sh	$72.45	−$131K	62,025
2026-01-21	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−2,735 sh	$72.45	−$198K	59,290
2026-01-07	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−1,974 sh	$72.23	−$143K	63,832
2025-08-06	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−30.9K sh	$42.73	−$1.32M	65,806
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−42.2K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−136K sh	—	—	0
2025-06-05	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+42.2K sh	—	—	42,200
2025-03-20	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−7,935 sh	$31.06	−$246K	96,720
2025-01-21	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−1,622 sh	$28.59	−$46.4K	106,320
2025-01-21	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−1,665 sh	$28.59	−$47.6K	104,655
2025-01-06	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+50K sh	—	—	50,000
2025-01-06	RNAMAvidity Biosciences, Inc.A Award	Chief Financial Officer	AAward	+25K sh	—	—	107,942
2024-12-18	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−11.2K sh	$32.66	−$364K	82,942
2024-11-06	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+13.9K sh	$6.57	+$91.2K	107,968
2024-11-06	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−65.2K sh	—	—	0
2024-11-06	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−13.9K sh	—	—	60,125
2024-11-06	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−27.3K sh	$46.22	−$1.26M	94,093
2024-11-06	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+65.2K sh	$8.82	+$575K	159,275
2024-11-06	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−65.2K sh	$45.33	−$2.95M	94,093
2024-11-06	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−13.9K sh	$45.33	−$629K	94,093
2024-09-23	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−11.5K sh	$44.00	−$506K	96,355
2024-09-19	RNAMAvidity Biosciences, Inc.A Award	Chief Financial Officer	AAward	+25K sh	—	—	107,865
2024-09-19	RNAMAvidity Biosciences, Inc.A Award	Chief Financial Officer	AAward	+25K sh	—	—	121,355
2024-06-26	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+136K sh	—	—	136,139
2024-06-18	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−11.2K sh	$39.13	−$439K	57,865
2024-06-17	RNAMAvidity Biosciences, Inc.A Award	Chief Financial Officer	AAward	+25K sh	—	—	82,865
2024-06-17	RNAMAvidity Biosciences, Inc.A Award	Chief Financial Officer	AAward	+25K sh	—	—	69,093
2024-06-12	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−104K sh	—	—	65,182
2024-06-12	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−104K sh	$35.72	−$3.72M	44,093
2024-06-12	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+104K sh	$8.82	+$919K	148,338
2024-05-14	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+75K sh	$8.82	+$662K	119,093
2024-05-14	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−75K sh	$28.28	−$2.12M	44,093
2024-05-14	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−75K sh	—	—	169,427
2024-03-13	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−40K sh	$24.52	−$981K	44,093
2024-03-13	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+40K sh	$8.82	+$353K	84,093
2024-03-13	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−40K sh	—	—	244,427
2024-01-22	RNAMAvidity Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−1,616 sh	$10.13	−$16.4K	16,884
2024-01-20	RNAMAvidity Biosciences, Inc.A Award	Chief Financial Officer	AAward	+22.5K sh	—	—	27,209
2024-01-20	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+106K sh	—	—	106,000
2023-09-11	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+74K sh	—	—	74,000
2023-06-15	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+26.6K sh	—	—	26,642
2023-02-14	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+7,000 sh	—	—	7,000

Recent filings

Accepted (ET)
Apr 34
MacLean Michael F0001383731-26-000006
SEC(opens sec.gov)
Feb 274
MacLean Michael F0001193125-26-082300
SEC(opens sec.gov)
Jan 234
MacLean Michael F0001599901-26-000023
SEC(opens sec.gov)
Jan 94
MacLean Michael F0001599901-26-000010
SEC(opens sec.gov)
Aug 154
MacLean Michael F0001599901-25-000161
SEC(opens sec.gov)
Jul 284
MacLean Michael F0000950170-25-099264
SEC(opens sec.gov)
Jun 64
MacLean Michael F0000950170-25-083229
SEC(opens sec.gov)
Mar 214
MacLean Michael F0001599901-25-000069
SEC(opens sec.gov)
Jan 234
MacLean Michael F0001599901-25-000041
SEC(opens sec.gov)
Jan 84
MacLean Michael F0001599901-25-000023
SEC(opens sec.gov)

Companies

Address

C/O RESEARCH ALLIANCE CORPORATION III 600 FIFTH AVENUE, 23RD FLOOR

NEW YORK, NY, 10020